ASSESSMENT OF THE OVERWEIGHT INFLUENCE ON LIVER FIBROSIS
DOI:
https://doi.org/10.11603/1811-2471.2020.v.i4.11635Keywords:
fibrosis, overweight and obesityAbstract
SUMMARY. Chronic diffuse inflammatory liver disease, overweight and obesity in recent decades continue to be a serious cause of morbidity, mortality and disability.
The aim – to compare the effect of excess body weight on the fibrosis course in patients with hepatic steatosis and patients with convalescence of HCV infection.
Material and Methods. The study included 115 patients with liver fibrosis. Participants were divided into two groups. Group 1 included patients treated for HCV infection (n=56), group 2 consisted of patients with NAFLD (n=59). Patients from each group were divided into subgroups depending on their body weight according to the classification of BMI (adopted by the WHO (1997).
Results. The presence of excess body weight significantly affects the clinical course of the pathological liver fibrosis process which manifested itself in the development of cytolytic syndrome. There was a growth rates of liver function tests in the biochemical blood analysis with increasing body weight. A direct moderate relationship between BMI and ALT, AST was detected. Transaminases were also correlated with liver fibrosis and elastography data. Simultaneously, this category of patients is diagnosed with prognostically unfavorable indicators of lipid metabolism disorders, and fibrosis itself tends to progress.
Conclusions: 1. The correlation of BMI with the level of ALT and AST in the blood was established (r=0.679, p<0.05 and r=0.674, p<0.05), which with a further increase in excess body weight can lead to the transition from steatosis to steatohepatitis.
- According to the lipid profile, the dependence of lipid spectrum disorders on BMI was established. People with overweight and obesity grade I are more predisposed to hypercholesterolemia, hypertriglyceridemia (r=0.318, p<0.05) on the background of reduced HDL cholesterol (r=-0.219, p<0.05). These disorders are an unfavorable factor in the course of steatosis, and in combination with fibrosis contributes to its progression.
- Overweight and obesity are the basis for the development of fibrotic processes in the liver (r=0.74, p<0.05), and its significant increase leads to pronounced fibrotic changes (F2 –F3 by METAVIR).
References
Vovk, E.I. (2013). Nealkogolnaya zhirovaya bolezn pecheni: ot nauchnykh dostizheniy k klinicheskim algoritmam [Non-alcoholic fatty liver disease: from scientific advanc es to clinical algorithms]. Meditsinskiy sovet – Medical Counsel, 10, 46-53 [in Russian].
Brandt, M.L., Harmon, C.M., & Helmrath, M.A. (2010). Morbid obesity in pediatric diabetes mellitus: surgicaloptionsandout-comes. Nature Reviews Endocrinology, 6, 637-664
Loguercio, C., Tiso, A., & Cotticelli, G. (2011). Management of chronic liver disease by general practitioners in southern Italy: unmet educational needs. Digestive and Liver Disease, 43, 736-741.
Byrne, C.D., & Targher, G. (2014). Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 34 (6), 1155-1161.
Arun J. S. (2002). AGA Technical review on nonalcoholic fatty liver disease. Gastroenterology, 123, 1705-1725.
Byrne, C.D., & Targher, G. (2015). NAFLD: a multisystem disease. Journal of Hepatology, 62 (1), Suppl, 47-64.
Kharchenko, N.V., Skrypnik, I.N., & Kharchenko, V.V. (2017). Nealkogolnaya zhirovaya bolezn pecheni: terapevticheskiye vozmozhnosti L-karnitina [Non-alcoholic fatty liver disease: therapeutic potential of L-carnitine]. Zdorovia Ukrainy – Health of Ukraine, 1 (43), 28–30 [in Russian].
Stepanov, Yu.M. (2014). Steatoz pecheni i steatogepatit – neizbezhnost smeshannogo geneza [Liver steatosis and steatohepatitis - inevitability of mixed genesis]. Gastroyenterologіya – Gastroenterology, 4 (54), 136-142 [in Russian].
Zvyagintseva, T.D., & Glushchenko, S.V. (2017). Nealkogolnyy steatogepatit: mekhanizmy razvitiya i taktika lecheniya [Non-alcoholic steatohepatitis: mechanisms of development and treatment tactics]. Zdorovia Ukrainy – Health of Ukraine, 1 (43), 4041 [in Russian].
Diagnostika i lecheniye bolnykh s nealkogolnoy zhirovoy boleznyu pecheni: prakticheskiye rekomendatsii Amerikanskoy assotsiatsii po izucheniyu zabolevaniy pecheni, Amerikanskogo kolledzha gastroenterologii i Amerikanskoy gastroenterologicheskoy assotsiatsii (2014) [Diagnosis and treatment of patients with non-alcoholic fatty liver disease: A practical guideline from the American Association for the Study of Liver Diseases, the American College of Gastroenterology, and the American Gastroenterological Association]. Suchasna gastroyenterologіya – Modern Gastroenterology, 3 (77), 89-104 [in Russian].
Tomeno, W., Yoneda, M., & Imajo, K. (2013). Emerging drugs for non-alcoholic steatohepatitis. Expert Opinion Emerging Drugs, 18 (3), 279-290.
Xarchenko, N.V., & Babak, O.Ya. (2016). Gastroenterologiya: pidruchnyk: u 2 tomakh [Gastroenterology: textbook: in 2 volumes]. Kirovograd: Polium [in Ukrainian].
Solomentseva, T.A. (2017). Nealkogolnaya zhirovaya bolezn pecheni i metabolicheskiye narusheniya: chto pervichno? [Non-alcoholic fatty liver disease and metabolic disorders: what comes first?] Suchasna gastroyenterologіya – Modern Gastroenterology, 6 (98), 51-57 [in Russian].
Samsonov, A.A., Plotnikova, E.Yu., & Nikushkina, I.N. (2013). Alkogolnaya bolezn pecheni i alkogolizm – dve bolezni i odna problema [Alcoholic liver disease and alcoholism are two diseases and one problem]. Meditsinskiy sovet – Medical Counsel, 10, 38-41 [in Russian].
Tirikova, O.V., Kozlova, N.M., Eliseyev, S.M., & Gumerov, R.R. (2015). Problemy diagnostiki nealkogolnoy zhirovoy bolezni pecheni [Problems in the diagnosis of non-alcoholic fatty liver disease]. Sibirskiy meditsinskiy zhurnal – Siberian Medical Journal, 7, 33-39 [in Russian].
Scaglioni, F. (2011). ASH and NASH. Digestive Diseases, 29 (2), 202-210.
Komshilova, K.A., & Troshina, K.A. (2015). Ozhireniye i nealkogolnaya zhirovaya bolezn pecheni: metabolicheskiye riski i ikh korrektsiya [Obesity and non-alcoholic fatty liver disease: metabolic risks and their correction]. Ozhireniye i metabolizm – Obesity and Metabolism, 12 (2), 35-39 [in Russian].
Starodubova, A.V. (2014). Izbytochnaya massa tela i ozhireniye kak faktory riska nealkogolnoy zhirovoy bolezni pecheni [Overweight and obesity as risk factors for non-alcoholic fatty liver disease]. Arkhiv vnutrenney meditsiny – Achieve of Internal Medicine, 5 (19), 10-20 [in Russian].
Day C.P., James O.F. (1998). Steatohepatitis: a tale of two “hits”? Gastroenterology, 114, 842-845.
Roytberg, G.E., Sharkhun, O.O., Kondratova, N.V., & Ushakova, T.I. (2015). Rol metabolicheskogo sindroma i ego komponentov v patogeneze i progressirovanii nealkogolnogo steatogepatita [The role of metabolic syndrome and its components in the pathogenesis and progression of non-alcoholic steatohepatitis]. Gepatologiya – Hepatology, 5, 30-36 [in Russian].
Kokovina, Yu.V., & Vishnevskaya, O.N. (2015). Primeneniye kombinirovannykh gepatoprotektorov u patsiyentov s diffuznymi izmeneniyami pecheni i s izmenennym lipidnym spektrom [The use of combined hepatoprotectors in patients with diffuse liver changes and altered lipid spectrum]. Russkiy meditsinskiy zhurnal – Russian Medical Journal, 2, 86-88 [in Russian].
Okovityy, S.V. (2015). Mitokhondrialnaya disfunktsiya pri metabolicheskom sindrome [Mitochondrial dysfunction in metabolic syndrome]. Effektivnaya farmakoterapiya – Effective Pharmacotherapy, 16, 46-48 [in Russian].
Angulo, P., Keach, J.C., & Battsetal, K.P. (1999). Independent predictor sofliver fibrosis in patients with non-alcoholicsteatohepatitis. Hepatology, 30 (6), 1356-1362.
Filippova, O.Yu. (2011). Morfolohichni parametry nealkoholnoho ta alkoholnoho steatohepatytiv u khvorykh iz patolohiieiu biliarnoho traktu [Morphological parameters of non-alcoholic and alcoholic steatohepatitis in patients with biliary tract pathology]. Svit medytsyny ta biolohii – World of Medicine and Biology, 1, 107-110 [in Ukrainian].
Bełtowski, J. (2012). Leptin and the regulation of endothelial function in physiological and pathological conditions. Clinical and Experimental Pharmacology Physiology, 39 (2), 168-178.
Chernova, V.M. (2017). Mnogofaktornost patogenezane alkogolnoy zhirovoy bolezni pecheni [Multifactorial pathogenesis of alcoholic fatty liver disease]. Suchasna hastroenterolohіia – Modern Gastroenterology, 6 (98), 92-101 [in Russian].
Chesnokova, L.V., Petrov, I.M., Troshina, I.A., & Medvedeva, I.V. (2013). Soderzhaniye provospalitelnykh tsitokinov v zavisimosti ot stadii fibroza u bolnykh s metabolicheskim sindromom i nealkogolnoy zhirovoy boleznyu pecheni [Content of proinflammatory cytokines depending on the stage of fibrosis in patients with metabolic syndrome and non-alcoholic fatty liver disease]. Klinicheskaya medetsina – Clinicl Medicone, 12 (91), 34-38.[in Russian].
Wieckowska, A., Papouchado, B.G., & Li, Z. (2008). Increased hepatic and circulating interleukin-6 levels in human non-alcoholic steatohepatitis. Am. J. Gastroenterol., 103, 1372-1379.
Buyeverov, A.O., & Bogomolov, P.O. (2012). «Tsitokinovyy vzryv» i progressirovaniye nealkogolnogo steatogepatita ["Cytokine burst" and the progression of non-alcoholic steatohepatitis]. Klin. perspektivy gastroenterol. Gepatol. – Clinical Prospects of Gastroenterology and Gepatology, 5, 12-18 [in Russian].
Abiru, S., Migita, K., & Maeda, Y., (2006). Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Internatial, 26, 39-45.
Petta, S., Grimaudo, S., & Camma, C. (2012). IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 56 (6), 1356-1362.
Hernaez, R., Lazo, M., & Bonekamp, S. (2011). Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: ameta-analysis. Hepatology, 54 (3), 1082-1090.
Suh, Y.G., & Jeong, W.I. (2011). Hepatic stellate cells and innate immunity in alcoholic liver disease. World Journal of Gastroenterology, 17 (20), 2543-2551.
Mammayev, S.N., Bagomedova, N.V., & Bogomolov, P.O. (2007). Tsitokinovaya sistema pri nealkogolnom steatogepatite [The cytokine system in non-alcoholic steatohepatitis]. Ros. zhurn. gastroenterol. gepatol. Koloproktol. – Russian Journal of Gastroenterology, Gepatology, Coloproctology, 4, 35-39 [in Russian].
Leeming, D., He, Y., & Veidal, S. (2011). A novel marker fo rassessment of liver matrix remodeling: anenzyme-linked immune sorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers, 16 (7), 61-628.
Hospodarskyy, I.Ya., Gavryliuk, N.M., & Prokopchuk, O.V. (2018). Ua Patent No u 2017 10483. Kyiv: The State Enterprise “Ukrainian Industrial Property Institute”.
Colak, Y., Senates, E., & Yesil, A. (2013). Assessment of endothelial function in patients with non-alcoholic fatty liver disease. Endocrine, 43, 100-107.
Bobrov, A.N. (2011). Tsirroz pecheni: etiologicheskiye, epidemiologicheskiye, kliniko-diagnosticheskiye i profilakticheskiye aspekty po dannym 15-letnego (1996-2010 gg.) nablyudeniya v mnogoprofilnom gospitale [Cirrhosis of the liver: etiological, epidemiological, clinical, diagnostic and preventive aspects according to the data of 15-year (1996-2010) observation in a multidisciplinary hospital]. Candidate’s Extended abstract. Moscow [in Russian].
Charlton, M.R., Burns, J.M., & Pedersen, R.A. (2011). Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology, 141, 1249-1253
Spahis, S., Delvin, E., Borys, J.M., & Levy, E. (2017). Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal, 26 (10), 519-541.
Komshilova, K.A., Troshina, E.A., & Ershova, E.V. (2014). Adiponektin i pokazateli metabolizma glyukozy i lipidov na raznykh kliniko-morfologicheskikh stadiyakh nealkogolnoy zhirovoy bolezni pecheni u bolnykh abdominalnym ozhireniyem [Adiponectin and indicators of glucose and lipid metabolism at different clinical and morphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity]. Terapevt. Arkhiv – Therapeutic Archieve, 10, 27-32 [in Russian].
Balukova, E.V., & Uspenskiy, Yu.P. (2014). Nealkogolnaya zhirovaya bolezn pecheni i metabolicheskiy sindrom [Non-alcoholic fatty liver disease and metabolic syndrome]. Gastroenterologiya – Gastroenterology, 1, 45-48 [in Russian].
Vyalov, S.S. (2014). Zhirovaya bolezn pecheni: osobennosti patogeneza, diagnostika i terapevticheskiy potentsial [Fatty liver disease: features of pathogenesis, diagnosis and therapeutic potential]. Consilium Medicum. Gastroenterologiya – Consilium Medicum. Gastroenterology, 8, 72-77 [in Russian].
Manne, V., Handa, P., & Kowdley, K.V. (2018). Pathophysiology of nonalcoholic fatty liver disease / nonalcoholic steatohepatitis. Clinical Liver Disease, 22 (1), 23-37.
Melnichenko, G.A., Eliseyeva, A.Yu., & Mayevskaya, M.V. (2012). Rasprostranennost nealkogolnoy zhirovoy bolezni pecheni pri ozhirenii i eye vzaimosvyaz s faktorami riska serdechno-sosudistykh zabolevaniy i sakharnogo diabeta 2-go tipa [Prevalence of non-alcoholic fatty liver disease in obesity and its relationship with risk factors for cardiovascular diseases and type 2 diabetes mellitus]. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii – Russian Journal of Gastroenterology, Gepatology, Coloproctology, 5, 45-52 [in Russian].
Kwon, Y.M., Oh, S.W., & Hwang, S.S. (2012). Association of non-alcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am. J. Gastroenterology, 107, 1852-1858.
Fadyeyenko, G.D., & Nikiforova, Ya.V. (2016). Osoblyvosti kharchovoi povedinky khvorykh na nealkoholnyi steatohepatyt z nadlyshkovoiu masoiu tila abo ozhyrinniam na tli arterialnoi hipertenzii [Features of eating behavior of patients with non-alcoholic steatohepatitis with overweight or obesity on the background of hypertension]. Suchasna hastroenterolohiia – Modern Gastroenterology, 2, 7-14 [in Ukrainian].
Mittendorfer, B., Yoshino, M., Patterson, B.W., & Klein, S. (2016). VLDL triglyceride kinetics in lean, overweight, and obese men and women. Journal of Clinical Endocrinology & Metabolism, 101, 4151-4160.
Dalleck, L.C., Van Guilder, G.P., & Richardson, T.B. (2014). A community-based exercise intervention transitions metabolically abnormal obese adults to a metabolically healthy obese phenotype. Diabetes, Metabolic Syndrome and Obesity, 7, 369-380.
Angulo, P., Hui, J.M., & Marchesini, G. (2007). NAFLD fibrosis score A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45 (4), 846-854.
Machado, M.V., & Cortez-Pinto, H. (2013). Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. Journal of Hepatology, 58, 1007-1019.
Toouli, J., Fried, M., & Khan, A.G. (2009). Obesity World Gastroenterology Organisation Global Guideline. WGO Global Guideline. Obesity, 30.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
